CBD Isolate Oral Pain Reliever Formulation for Faster Action

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing oral pain relievers face challenges such as delayed onset of action, gastrointestinal side effects, liver or kidney toxicity, risk of dependency, and unpredictable efficacy due to bioavailability and individual variability, particularly with traditional NSAIDs and opioids.

Innovation Solution

A novel oral pharmaceutical composition combining cannabidiol isolate, acetaminophen, and ibuprofen, with specific weight percentages and excipients like starch and polyvinylpyrrolidone, formulated for rapid or controlled release, optimizing drug delivery and efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional oral analgesics (NSAIDs, acetaminophen, ibuprofen) are used, then pain relief is provided, but delayed onset of action and gastrointestinal side effects occur

Engineering Contradiction:

Improvepain relief efficacyVSAvoidonset of action time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent combines CBD isolate with traditional analgesics (acetaminophen and/or ibuprofen) to create a composite pharmaceutical formulation. This composite approach leverages the synergistic effects of CBD's anti-inflammatory properties combined with the analgesic actions of traditional drugs, achieving both rapid onset and sustained pain relief while reducing gastrointestinal side effects through CBD's protective mechanisms

Inventive Principle:

Principle #40Composite materials

2Reliability

If traditional oral analgesics are used, then pain relief is achieved, but gastrointestinal side effects and liver or kidney toxicity occur

Engineering Contradiction:

Improvepain relief efficacyVSAvoidgastrointestinal side effects and organ toxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

CBD isolate serves as an intermediary substance that modulates the pharmacological effects of traditional analgesics. It enhances pain relief through multiple mechanisms while simultaneously protecting gastrointestinal tissue and reducing hepatotoxicity and nephrotoxicity associated with conventional drugs, acting as a protective mediator

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If opioid-based medications are used, then strong pain relief is provided, but risk of dependency and abuse increases

Engineering Contradiction:

Improvepain relief efficacyVSAvoiddependency and abuse risk

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent changes the pharmacological parameters by substituting opioid-based medications with a CBD-isolates-analgesic combination. This formulation achieves comparable or superior pain relief through multiple mechanisms (endocannabinoid system modulation, COX inhibition, central analgesia) while completely eliminating the risk of opioid dependency and abuse

Inventive Principle:

Principle #35Parameter changes

4Reliability

If cannabinoid formulations are used, then pain relief and anti-inflammatory effects are provided, but unpredictability due to bioavailability and biodiversity occurs

Engineering Contradiction:

Improvepain relief and anti-inflammatory efficacyVSAvoidbioavailability consistency and efficacy predictability

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The patent extracts and isolates pure CBD from the complex cannabinoid mixture, removing unpredictable components while retaining the therapeutic active ingredient. This isolation process ensures consistent bioavailability and predictable pharmacological effects by eliminating variability associated with full-spectrum cannabis extracts

Inventive Principle:

Principle #2Taking out (Extraction)

Data Source

PatentUS20250302770A1Oral pain reliever composition, pharmaceutical formulation, and process for making composition and formulation including cannabidiol isolate with select active ingredients

Publication Date: 2025.10.02 CAVENDER MICHAEL

AI summary

A chemical composition for an oral pharmaceutical product is described having a therapeutically effective amount of one or more active pharmaceutical ingredients (API) including acetaminophen and ibuprofen in combination with a cannabidiol (CBD) isolate.